[1] Xu Hujun Ruan Jia an Gao Feng Li Min,.Clinical Study on Treatment of Hyperlipidemia with Shateng Hongqu Soft Capsule [J]. Modern Traditional Chinese Medicine, 2019, (05): 61-64. [doi: 10.13424/j.cnki.mtcm.2019.05.019]
Clinical Study on Treatment of Hyperlipidemia with Shateng Hongqu Soft Capsule
- Article number:
- 1672-0571(2019)05-0061-04
- ZTFLH:
- R543
- Code:
- A
- Abstract:
- To study the effect of Shateng Hongqu Soft Capsule on hyperlipidemia and inflammatory factors TNF - a and IL -6. Methods: The experimental design was based on the principles of double blindness, randomization and parallel control. The treatment group was given Shateng Hongqu Soft Capsules, while the control group was given placebo for 90 days. The effective cases of the experiment were 58 cases in the treatment group and 56 cases in the control group. After the blindness was uncovered, the effects of Shateng Hongqu Soft Capsule on inflammatory factors TNF – a and IL -6 in patients with hyperlipidemia were analyzed. Results: TThe total cholesterol ( TC) effective rate was 65.52%, the triglyceride ( TG) efficiency was 51. 72%, and the high density lipoprotein ( HDL - C) was 44. 83%, which were significantly higher than those of the placebo control group ( 7. 14%, 8. 93% and 28. 57%) . Through comparative analysis, TC and TG values in the treatment group were significantly lower than those in the control group, HDL - C values were significantly higher than those in the control group, and inflammatory factors TNF - a and IL - 6 were lower than those in the control group, with statistical significance. Conclusion: Shateng Hongqu Soft Capsule can not only effectively regulate the blood lipid level of patients with hyperlipidemia, but also inhibit vascular atherosclerosis by reducing TNF - a and IL -6.
References:
[1]米良荣.2007-2009年我院口服降血脂药物应用分析[J].中国医药导刊,2011,13(2):307-308.
[2]赵丹丹.载脂蛋白A5?C3和E基因多态性与高脂血症痰瘀互阻证及其疗效的关系[D].北京:中国中医科学院,2007.
[ 3] The medical letter, Inc. Choice of lipid— regulating drugs [ J] . Medlettdrug Ther,2001,43( 1105) :43.
[4]张振强.内科学[M].西安:第四军医大学出版社,2013:195-199.
[5]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:254-257.
[6]李剑红,王丽敏.2010年我国成年人血脂异常流行特点[J].中华预防医学杂志,2012,46(5):414-418.
[7]血脂治疗现状调查协作组.我国高脂血症治疗现状的调查[J].中华心血管病杂志,2001,29(1):15~17.
[8]张文文,王秀梅.血脂水平对sPESI评分为高危的急性肺动脉栓塞患者的预测作用[J].中国实用医药,2016,11(29):10-12.
[ 9] American Gastroenterological Association. A – merican Gastroenterological AssociationMedi - cal Position Statement: nonalcoholic fatty liverdisease. Gastroenterology,2002,123:1702 -1704.
[10]刘朝降.2型糖原病非增殖性视网膜病变血脂异常与膜岛素抵抗的关系[J].中国医疗前沿,2011,17(6):26-27.
[ 11] Amstrong VM. The association between LP( a) eoneentrations and angiographically assessed coronary atheroselerosis [ J] . Atheroselerosis,1989,62( 4) :249.
[ 12] Napolip D, Taccardi AA, Oliver M, et al. Statins and stroke: Evidence forCholesterol - Independent Effects [ J] . Eur Heart J,2002,23( 24) :1908 -1921.
[ 13] Popa C, Netea M G, van Riel P L, et al. The role of TNF - alpha in chronic inflamematory conditions, intermediary metabolism, and cardiovascular risk [ J] . J Lipid Res. 2007,48( 4) : 751 -762.
[ 14] Cruickshank AM, Oldroyd KG, Cobbs. et al. Serum IL- 6 in suspected myocardial infarction [ J] . Lancet.1994; 343( 8903 ) ;974.
[ 15] Al Ian Ml, Rosario S, David J. Vaseular effects of HMG- Co A reductase inhibitors( statins) unrelated cholesterol lowering: new concepts for cardiovascular disease. Cardiovase Res, 2001, 49 ( 2) : 281 -287.
Memo
基金项目：陕西秦岭中草药应用开发工程技术研究中心（２００８ＺＤＧＣ－３２）